Loading data for HOWL — first visit, this takes a few seconds.
Werewolf Therapeutics Inc... (HOWL)
NasdaqCM: HOWL
· Real-Time Price · USD
0.41
+0.00 (0.00%)
At close: Aug 19, 2026, 4:47 PM
Werewolf Therapeutics Inc. (HOWL) Stock Price, Analysis & Data
0.00% (1D)
No data available
| Bid | 0.29 |
| Market Cap | 20.01M |
| Revenue (ttm) | 21M |
| Net Income (ttm) | -34.61M |
| Beta | 0.29 |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.42 |
| P/B (ttm) | 1.23 |
| P/S (ttm) | 0.95 |
| Earnings Date | Oct 30, 2026 |
| Ask | 0.53 |
| Volume | 58,525 |
| Avg. Volume (20D) | 706,629 |
| Open | 0.41 |
| Previous Close | 0.41 |
| Day's Range | 0.40 - 0.42 |
| 52-Week Range | 0.27 - 2.38 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead prod...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 30, 2021
Employees 39
Stock Exchange NasdaqCM
Ticker Symbol HOWL
Website https://werewolftx.com
Financial Performance
In 2025, Werewolf Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 1.89M. Earnings were -60.82M, a decrease of -13.75%.
Financial StatementsEarnings Surprise
Werewolf Therapeutics has released their quarterly earnings on Jul 31, 2026:
Werewolf Therapeutics Inc. is scheduled to release its earnings on Oct 30, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2